Misinformation Contributing To Slower Biosimilar Uptake, Execs Claim
‘All Stakeholders Responsible’ For Change
Dispelling myths around biosimilar efficacy and safety may be crucial to driving uptake of biosimilars, executives from Sandoz and Boehringer Ingelheim have argued in an opinion piece in the journal, BioDrugs, as they asserted it was the “responsibility of all stakeholders to challenge biosimilar disparagement and misinformation when encountered.”
You may also be interested in...
Sandoz CEO Richard Saynor says he sees promising signs from the US biosimilars market that suggest it is beginning to meet its potential, albeit remaining many years behind the European market.
Increasing access and use of lower cost biosimilars by combatting disparagement and misinformation is more important now than ever, as the COVID-19 pandemic cripples economies across the globe, argues Sandoz’ executive director for scientific affairs, Hillel Cohen.
Two agencies to take action against false or misleading communications about biosimilars, impediments to sampling, and anticompetitive patent settlement agreements; to hold public workshop in March.